AU2001257227A1 - Aniline Disulfide Derivatives for Treating Allergic Diseases - Google Patents
Aniline Disulfide Derivatives for Treating Allergic DiseasesInfo
- Publication number
- AU2001257227A1 AU2001257227A1 AU2001257227A AU2001257227A AU2001257227A1 AU 2001257227 A1 AU2001257227 A1 AU 2001257227A1 AU 2001257227 A AU2001257227 A AU 2001257227A AU 2001257227 A AU2001257227 A AU 2001257227A AU 2001257227 A1 AU2001257227 A1 AU 2001257227A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- substituted
- alkenyl
- disulfide derivative
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
ANILINE DISULFIDE DERIVATIVES FOR TREATING ALLERGIC
DISEASES
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to the treatment of allergic diseases. More particularly, the present invention relates to therapeutic and prophylactic use of certain disulfide derivatives for treating or preventing allergic diseases.
Description of the Related Art
Antihistamines and mast cell stabilizers are two types of drugs currently used topically to treat allergic diseases. Antihistamine drugs are used to interrupt the allergic effects that histamine causes after it has been released from a mast cell. Many topical antihistamine drugs are marketed. For example, emedastine difumarate and levocabastine hydrochloride are available for ocular allergies (see Ophthalmic Drug Facts 1999, Facts and Comparisons, St. Louis, MO, pp. 59 - 80).
Mast cell stabilizers prevent mast cells from "degranulating" or releasing histamine and other components or "mediators" during an allergic reaction. Examples of ophthalmic drugs marketed as mast cell stabilizers include olopatadine (see U.S. Patent No. 5,641 ,805) and cromolyn sodium.
U.S. Patent No. 4,705,805 discloses certain disulfide derivatives that are useful as anti-thrombotic agents. The disulfide derivatives suppress blood platelet aggregation. The 705 patent does not disclose the use of disulfide derivatives in the treatment of allergic diseases.
Summary of the Invention
The present invention provides methods for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung. The methods may also be used to treat manifestations of systemic mastocytosis. The methods of the present invention comprise topically or systemically administering to a patient a mast cell stabilizing disulfide derivative of the formula
(I)
wherein X is -NH-C(=O)-R, or -NH-C(=O)-OR;
R = H; (un)substituted phenyl; (un)substituted benzyl; or Ci - Cβ alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C -C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5 - 7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - C6 alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2;
R2 = Ci - C3 alkyl; and
R3 and R4 are independently H; benzyl; Ci - Cβ alkyl or alkenyl; C4-C7 cycloalkyl; (un)substituted aryl; or (un)substituted 5 - 7 membered heterocyclic ring; wherein optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
The present invention is also directed toward topically or systemically administrable compositions for treating or preventing allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and treating or
preventing manifestations of systemic mastocytosis, wherein the compositions comprise a disulfide derivative of formula (I).
Detailed Description of the Invention
The present invention relates to novel disulfide derivatives of formula (I) wherein
X is -NH-C(=O)-R;
R is -C(-R5)-C=C(-R6)R7 or -C(-R5)-C(-OH)R6; R5 is H, Ci - C3 alkyl;
R6 is H, Ci - C3 alkyl or alkenyl; and R7 is H, d - C4 alkyl or alkenyl.
The remaining disulfide derivatives of formula (I) are known or are commercially available from sources such as Aldrich Chemical Company (Sigma Aldrich Library of Rare Chemicals) in Milwaukee, Wisconsin and Maybridge Chemical Company Ltd. in the U.K. The novel and known disulfide derivatives of formula (I) can be made using known techniques, such as those described in Domagala JM et al. Biorqanic and Medicinal Chemistry volume 5 No. 3 pages 569-79 (1997), and US patent No. 4,705,805 (Yamotsu K. et al., 1987). The entire contents of both of these references are incorporated by reference.
Preferred compounds of formula (I) are those wherein the X substituents are in the ortho position and wherein X = -NH-C(=O)-R; and
R = Ci - Cβ alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C4-C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5-7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
Most preferred are compounds wherein R = Ci - C5 alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C -C7 cycloalkyl,
(un)substituted aryl, or (un)substituted 5 - 7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
Compounds of formula (I) may be administered topically (i.e., local, organ-specific delivery) or systemically by means of conventional topical or systemic formulations, such as solutions, suspensions or gels for the eye and ear; nasal sprays or mists for the nose; metered dose inhalers for the lung; solutions, gels, creams or lotions for the skin; oral dosage forms including tablets or syrups for the gastrointestinal tract; and parenteral dosage forms including injectable formulations. The concentration of the compound of formula (I) in the formulations of the present invention will depend on the selected route of administration and dosage form. The concentration of the compound of formula (I) in topically administrable formulations will generally be about 0.00001 to 5 wt. %. For systemically administrable dosage forms, the concentration of the compound of formula (I) will generally range from about 10 mg to 1000 mg.
The preferred formulation for topical ophthalmic administration is a solution intended to be administered as eye drops. For solutions intended for topical administration to the eye, the concentration of the compound of formula (I) is preferably 0.0001 to 0.2 wt. %, and most preferably from about 0.0001 to 0.01 wt. %. The topical compositions of the present invention are prepared according to conventional techniques and contain conventional excipients in addition to one or more compounds of formula (I). A general method of preparing eye drop compositions is described below:
One or more compounds of formula (I) and a tonicity-adjusting agent are added to sterilized purified water and if desired or required, one or more excipients. The tonicity-adjusting agent is present in an amount sufficient to
cause the final composition to have an ophthalmically acceptable osmolality (generally about 150 - 450 mOsm, preferably 250 - 350 mOsm). Conventional excipients include preservatives, buffering agents, chelating agents or stabilizers, viscosity-enhancing agents and others. The chosen s ingredients are mixed until homogeneous. After the solution is mixed, pH is adjusted (typically with NaOH or HCI) to be within a range suitable for topical ophthalmic use, preferably within the range of 4.5 to 8.
Many ophthalmically acceptable excipients are known, including, foro example, sodium chloride, mannitol, glycerin or the like as a tonicity-adjusting agent; benzalkonium chloride, polyquatemium-1 or the like as a preservative; sodium hydrogenphosphate, sodium dihydrogenphosphate, boric acid or the like as a buffering agent; edetate disodium or the like as a chelating agent or stabilizer; polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acid,s polysaccharide or the like as a viscosity-enhancing agent; and sodium hydroxide, hydrochloric acid or the like as a pH controller.
If required or desired, other drugs can be combined with the disulfide derivatives of formula (I), including, but not limited to, antihistaminic agents,o anti-inflammatory agents (steroidal and non-steroidal), and decongestants. Suitable antihistaminic agents include emedastine, mapinastine, epinastine, levocabastine, loratadine, desloratadine, ketotifen, azelastine, cetirazine, and fexofenadine. The preferred antihistaminic agent for ophthalmic use is emedastine, which is generally included in topically administrable5 compositions at a concentration of 0.001 - 0.1 wt. %, preferably 0.05 wt. %. Suitable anti-inflammatory agents includemometasone, fluticasone, dexamethasone, prednisolone, hydrocortisone, rimexolone and loteprednol. Suitable decongestants include oxymetazoline, naphazoline, tetrahydrozoline, xylometazoline, propylhexedrine, ethylnorepinephrine, pseudoephedrine, ando phenylpropanolamine.
According to the present invention, the disulfide derivatives of formula (I) are useful for preventing and treating ophthalmic allergic disorders, including allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis; nasal allergic disorders, including allergic rhinitis and sinusitis; otic allergic disorders, including eustachian tube itching; allergic disorders of the upper and lower airways, including intrinsic and extrinsic asthma; allergic disorders of the skin, including dermatitis, eczema and urticaria; allergic disorders of the gastrointestinal tract, including systemic anaphylaxis resulting from ingestion of allergen and iatrogenic anaphylaxis caused by contrast agents used during diagnostic imaging procedures; and manifestations of systemic mastocytosis including hypotension.
The following examples are intended to be illustrative but not limiting.
Example 1 : Topical Ophthalmic Solution Formulation
Ingredient Concentration (wt.%)
Compound of formula (I) 0.0001 to 0.2
Dibasic Sodium Phosphate (Anhydrous) 0.5
Sodium Chloride 0.65
Benzalkonium Chloride 0.01
NaOH/HCI q.s. pH 6 - 8
Purified Water q.s. 100
Example 2: Topical Ophthalmic Gel Formulation
Ingredient Concentration (wt.%)
Compound of formula (I) 0.0001 to 0.2 Carbopol 974 P 0.8 Edetate Disodium 0.01 Polysorbate 80 0.05 Benzalkonium Chloride 0.01 NaOH/HCI q.s. pH 6 - 8 Water for Injection q.s. 100
Example 3: Synthesis of bis-(2-allylamidophenyl)-disulfide (II)
Vinylacetic acid (1.97 ml, 23.23 mmol) in thionyl chloride (2.7 ml, 34.85 mmol) was gently refluxed on an oil bath (~80°C) for two hours. After cooling, the liquid was evaporated on a rotary evaporator. The residue was dissolved in 20 ml of dioxane. 2-aminophenyl disulfide (Aldrich, 1.44g, 5.8 mmol) in 10 ml of dioxane was added and the resulting mixture was cooled to 10°C. Triethylamine (7 ml, 50 mmol) was added slowly under nitrogen. After addition, the mixture was stirred at 10°C for 1 hr and 70°C for 2 hr. After cooling, the solids were filtered off and the filtrate was concentrated. The residue was dissolved in 50 ml of CH2CI2, washed with 1 N HCI, (20 ml), saturated NaHCO3 (20 ml), water (20 ml) and saturated NaCI (20 ml) and then dried over MgSO4. The mixture was filtered and the solvent was concentrated. The residue was chromatographed on silicon gel eluting with 50% of ethyl acetate in hexane), giving 0.71 g of product which was solidified as yellowish solid (II). 1H NMR (CDCI3) δ 9.73 (s, 2H), 7.63-7.18 ( m, 8H), 6.21-5.90 (m, 2H), 5.27-513 (m, 4H), 3.16-3.13 ( d, 4H, J = 6.0). 13C NMR (CDCI3) δ 169.74 (C=O), 136.43 (C), 132.57 (CH), 131.94 (C), 129.52 (CH), 128.59 (CH), 126.92 (CH), 126.36 (CH), 118.38 (CH2), 40.95 (CH2). Analysis calculated for C20H20O2N2S2 requires: C, 62.47; H, 5.24; N, 7.28%. Found, C, 62.40; H, 5.28; N, 7.20%.
("I)
Example 4: Synthesis of bis-(2-(3-hydroxy-butyrylamido)phenyl)-disulfide
To a solution of 2-aminophenyldisulfide (1.5g, 6mmol) was added a solution of 3-hydroxy-butyric acid (2.5g, 24mmol) in THF (8ml) at 0 °C while stirring. s To this mixture was added dicyclohexylcarbodiimide (4.95g, 24mmol). After stirring at 5 °C or 1 h, the mixture was stirred overnight at room temperature. The solvent was evaporated on a rotavapor. Ethyl acetate (50ml) was added to the residue and washed with water (3X20ml) and saturated NaCI (20 ml) and then dried over MgSO4. The mixture was filtered and the solvent waso concentrated. The residue was chromatographed on silicon gel eluting with 50% of ethyl acetate in hexane), giving 0.31 g of product as white solid. 1H NMR (CDCI3) δ 7.80-7.76 (m, 2H), 7.48-7.43 ( m, 2H), 7.37-7.29 (m, 2H), 7.14-7.07 (m, 2H), 4.22-4.13 (m, 2H), 2.46-2.42 (m, 4H), 1.27-1.24 ( d, 6H, J = 6.0). 13C NMR (CDCI3) δ 172.88 (C=0), 139.42 (C), 134.60 (CH), 131.085 (CH), 130.11 (C), 126.96 (CH), 125.49 (CH), 65.77 (CH), 46.68 (CH2), 23.56 (CH3). ESI LC/MS [M+H]+: 421.
Example 5: Mast Cell Activity 0
Preparation of cell suspension
Methods detailing preparation of monodispersed HCTMC and mediator release studies with these cells have been described (US Patent No.
5,360,720 and Miller et al, Ocular Immunology and Inflammation, 4(1 ):39 - 495 (1996)). Briefly, human conjunctival tissue mast cells were isolated from post-mortem tissue donors obtained within 8 hours of death by various eye banks and transported in Dexsol® corneal preservation medium, or equivalent. Tissues were enzymatically digested by repeated exposure (30 min. at 37°C) to collagenase and hyaluronidase (2 X with 200 U each / gram0 tissue, then 2-4 X with 2000 U each / gram tissue) in Tyrode's buffer containing 0.1 % gelatin. (Tyrode's buffer (in mM): 137 NaCI, 2.7 KCI, 0.35 NaH2PO4, 1.8 CaCI2, 0.98 MgCI2, 11.9 NaHC03, and 5.5 glucose). Each digestion mixture was filtered over Nitex® cloth (100 μm mesh, Tetko,
Briarcliff Manor, NY) and washed with an equal volume of buffer. Filtrates were centrifuged at 825 x g (7 min). Pellets were resuspended in buffer then combined for enrichment over a 1.058 g/L Percoll® cushion. The enriched pellet was washed, resuspended in supplemented RPMI 1640 medium and incubated at 37°C to equilibrate.
Histamine release studies
Cells were harvested from the culture plate and counted for viability (trypan blue exclusion) and mast cell number (toluidine blue O). Mast cells (5000 / tube; 1 mL final volume) were challenged (37°C) for 15 min with goat-anti- human IgE (10 μg/mL) following treatment (15 minutes; 37°C) with test drug or Tyrode's buffer. Total and non-specific release controls were exposed to 0.1% Triton X-100 and goat IgG (10 μg/mL), respectively. The reaction was terminated by centrifugation (500 x g, 4°C, 10 min). Supernatants were stored at -20°C until analyzed for histamine content by RIA (Beckman Coulter, Chicago, IL).
Preparation of test drug solutions
All test drugs were made to solution immediately prior to use. Each was dissolved in DMSO at 10mM or greater concentration and then diluted in Tyrode's buffer containing 0.1 % gelatin over the concentration for evaluation.
Data Analysis
Inhibition of histamine release was determined by direct comparison of with anti-lgE challenged mast cells using Dunnett's t-test (Dunnett, "A multiple comparison procedure for comparing treatments with a control", J. Amer. Stat. Assoc. (1955), 50:1096-1121 ). An IC50 value (the concentration at which the test compound inhibits histamine release at a level of 50% compared to the positive control) was determined by 4-parameter logistic fitting using the Levenburg-Marquardt algorithm or by linear regression. The results are reported in Table 1.
Table 1
The data shown in Table 1 indicate that the compounds of formula (I) potently inhibit histamine release from human conjunctival mast cells in an in vitro model of allergic conjunctivitis.
Example 6: Topical Ophthalmic Solution Formulation
Ingredient Concentration (wt.%)
Compound of formula (I) 0.0001 to 0.2
Emedastine 0.001 to 0.1 Dibasic Sodium Phosphate (Anhydrous) 0.5
Sodium Chloride 0.65
Benzalkonium Chloride 0.01
NaOH/HCI q.s. pH 6 - 8
Purified Water q.s. 100
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims (18)
1. A method for preventing or treating an allergic disease of the eye, nose, skin, ear, gastrointestinal tract or lung and preventing or treating manifestations of systemic mastocytosis in a patient comprising administering
to the patient a composition comprising a disulfide derivative of the formula
wherein X is -NH-C(=O)-R, or -NH-C(=O)-OR;
R and R1 are independently H; (un)substituted phenyl; (un)substituted benzyl; or Ci - Cβ alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C4-C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5 - 7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - C6 alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2;
R2 is Ci - C3 alkyl; and
R3 and R4 are independently H; benzyl; Ci - Cβ alkyl or alkenyl; C4-C7 cycloalkyl; (un)substituted aryl; or (un)substituted 5 - 7 membered heterocyclic ring; wherein optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
2. The method of Claim 1 wherein the X substituents are in the ortho position and wherein
X = -NH-C(=O)-R; and
R = Ci - Cβ alkyl or alkenyl, optionally substituted with or terminated by
OH, OR2, NR3R4; C4-C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5-7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
3. The method of Claim 2 wherein R = Ci - C5 alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C4-C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5 - 7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
4. The method of Claim 3 wherein X is selected from the group consisting of
-NH-C(=O)-CH2CH=CH2; -NH-C(=O)-CH3; -NH-C(=O)-C(=CH2)-CH3; -NH-C(=O)-CH2-CH(-OH)-CH3; -NH-C(=O)-O-CH2-CH3; and -NH-C(=O)-
5. The method of Claim 1 wherein the disulfide derivative is administered to the patient in a topically administrable composition containing the disulfide derivative in an amount from about 0.00001 to 5 wt. %.
6. The method of Claim 5 wherein the disulfide derivative is present in an amount from about 0.0001 to 0.2 wt. %.
7. The method of Claim 6 wherein the disulfide derivative is present in an amount from about 0.0001 to 0.01 wt. %.
8. The method of Claim 1 wherein the disulfide derivative is administered to the patient in a systemically administrable composition containing the disulfide derivative in an amount from about 10 to 1000 mg.
9. A topically or locally administrable pharmaceutical composition for treating allergic diseases of the eye, nose, skin, ear or lung comprising a tonicity-adjusting agent in an amount sufficient to cause the composition to have an osmolality of 150 - 450 mOsm, a pharmaceutically acceptable preservative and a disulfide derivative of the formula
wherein X is -NH-C(=O)-R, or -NH-C(=O)-OR;
R and R1 are independently H; (un)substituted phenyl; (un)substituted benzyl; or Ci - C8 alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C4-C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5 - 7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; N02; and CO2R2;
R2 is Ci - C3 alkyl; and
R3 and R4 are independently H; benzyl; Ci - Cβ alkyl or alkenyl; C4-C cycloalkyl; (un)substituted aryl; or (un)substituted 5 - 7 membered heterocyclic ring; wherein optional substituents are selected from the group consisting of Ci - C6 alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
10. The pharmaceutical composition of Claim 9 wherein the X substituents are in the ortho position and wherein X = -NH-C(=O)-R; and
R = Ci - C8 alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C4-C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5-7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - Cβ alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
11. The pharmaceutical composition of Claim 10 wherein R = Ci - C5 alkyl or alkenyl, optionally substituted with or terminated by OH, OR2, NR3R4; C4-C7 cycloalkyl, (un)substituted aryl, or (un)substituted 5 - 7 membered heterocyclic ring; where optional substituents are selected from the group consisting of Ci - C6 alkyl or alkoxy; halogen; OH; CN; CF3; NO2; and CO2R2.
12. The pharmaceutical composition of Claim 11 wherein X is selected from the group consisting of -NH-C(=O)-CH2CH=CH2; -NH-C(=O)-CH3; -NH-C(=O)-C(=CH2)-CH3; -NH-C(=O)-CH2-CH(-OH)-CH3; -NH-C(=O)-O-CH2- CH3; and -NH-C(=O)-C(CH3)3.
13. The pharmaceutical composition of Claim 9 wherein the disulfide derivative is present in an amount from about 0.00001 to 5 wt. %.
14. The pharmaceutical composition of Claim 13 wherein the disulfide derivative is present in an amount from about 0.0001 to 0.2 wt. %.
15. The pharmaceutical composition of Claim 14 wherein the disulfide derivative is present in an amount from about 0.0001 to 0.01 wt. %.
16. A disulfide derivative of the formula
wherein X is -NH-C(=0)-R;
R is -C(-R5)-C=C(-R6)R7 or -C(-R5)-C(-OH)R6;
R ι5° ; is H, Ci - C3 alkyl; R6 is H, Ci - C3 alkyl or alkenyl; and R7 is H, Ci - C4 alkyl or alkenyl.
17. The disulfide derivative of Claim 16 wherein R is -C(-R5)-C=C(-R6)R7 and R5, R6, and R7 are H.
18. The disulfide derivative of Claim 16 wherein R is -C(-R5)-C(-OH)R6 , R5 is H, and R6 is CH3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20574600P | 2000-05-19 | 2000-05-19 | |
US60/205,746 | 2000-05-19 | ||
PCT/US2001/013242 WO2001090059A1 (en) | 2000-05-19 | 2001-04-25 | Aniline disulfide derivatives for treating allergic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001257227A1 true AU2001257227A1 (en) | 2002-02-21 |
AU2001257227B2 AU2001257227B2 (en) | 2005-04-07 |
Family
ID=22763478
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001257227A Ceased AU2001257227B2 (en) | 2000-05-19 | 2001-04-25 | Aniline Disulfide Derivatives for Treating Allergic Diseases |
AU5722701A Pending AU5722701A (en) | 2000-05-19 | 2001-04-25 | Aniline disulfide derivatives for treating allergic diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU5722701A Pending AU5722701A (en) | 2000-05-19 | 2001-04-25 | Aniline disulfide derivatives for treating allergic diseases |
Country Status (20)
Country | Link |
---|---|
US (2) | US6372802B2 (en) |
EP (1) | EP1289945B1 (en) |
JP (1) | JP2003534317A (en) |
KR (1) | KR20020093982A (en) |
CN (1) | CN1173697C (en) |
AR (1) | AR028565A1 (en) |
AT (1) | ATE272619T1 (en) |
AU (2) | AU2001257227B2 (en) |
BR (1) | BR0110845A (en) |
CA (1) | CA2408145A1 (en) |
DE (1) | DE60104690T2 (en) |
DK (1) | DK1289945T3 (en) |
ES (1) | ES2222370T3 (en) |
HK (1) | HK1050677A1 (en) |
MX (1) | MXPA02011480A (en) |
PL (1) | PL365459A1 (en) |
PT (1) | PT1289945E (en) |
TR (1) | TR200402299T4 (en) |
WO (1) | WO2001090059A1 (en) |
ZA (1) | ZA200208839B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045668A2 (en) * | 1999-12-20 | 2001-06-28 | Schering Corporation | Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
AU2276801A (en) * | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
UA82323C2 (en) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Novel combination of a glucocorticoid and pde-inhibitor for the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases |
EP1774575A2 (en) * | 2004-05-17 | 2007-04-18 | Cambrios Technology Corp. | Biofabrication of transistors including field effect transistors |
WO2006004757A2 (en) * | 2004-06-28 | 2006-01-12 | Alcon, Inc. | Topical formulations for treating allergic diseases |
US20130304180A1 (en) * | 2012-05-09 | 2013-11-14 | Michael L. Green | Catheter having dual balloon hydraulic actuator |
US11058444B2 (en) | 2017-12-11 | 2021-07-13 | Covidien Lp | Electrically enhanced retrieval of material from vessel lumens |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1232787A (en) | 1967-08-08 | 1971-05-19 | ||
US3663616A (en) | 1969-10-13 | 1972-05-16 | Sherwin Williams Co | Bis(2-carbamylphenyl)disulfides |
EP0062827B1 (en) | 1978-06-16 | 1986-07-23 | Kyowa Hakko Kogyo Co., Ltd | Novel benzamide derivatives |
JPS59205356A (en) * | 1983-05-10 | 1984-11-20 | Teikoku Hormone Mfg Co Ltd | Disulfanylbenzeneacetic acid derivative |
GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
US4923892A (en) | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
JPS6310784A (en) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | Dibenz(b,e)oxepin derivative, antiallergic agent and anti-inflammatory agent |
GB9020933D0 (en) | 1990-09-26 | 1990-11-07 | Ici Plc | Compound,preparation and use |
US5859017A (en) | 1994-04-01 | 1999-01-12 | Cell Therapeutics, Inc. | Method for inhibiting mast cell and basophil activation |
US5734081A (en) | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
US5463122A (en) | 1994-08-05 | 1995-10-31 | Warner-Lambert Company | Arylthio compounds |
US6001555A (en) | 1994-09-23 | 1999-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein |
JPH08253454A (en) * | 1994-12-26 | 1996-10-01 | Nisshin Flour Milling Co Ltd | Diphenyldisulfide compound |
JPH095926A (en) | 1995-04-18 | 1997-01-10 | Fuji Photo Film Co Ltd | Heat developable photosensitive material |
US5641805A (en) | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
US6225327B1 (en) | 1996-04-18 | 2001-05-01 | Alcon Laboratories, Inc. | Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications |
JP2894445B2 (en) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Compounds effective as CETP activity inhibitors |
JP3940201B2 (en) | 1997-05-20 | 2007-07-04 | 大塚製薬株式会社 | 3,3'-dithiodibenzohydroxamic acid |
JP3702382B2 (en) * | 1997-10-22 | 2005-10-05 | 参天製薬株式会社 | NF-κB activation inhibitor |
ATE302601T1 (en) * | 2000-05-19 | 2005-09-15 | Alcon Inc | COMPOSITIONS CONTAINING A BENZAMIDE DISULFIDE DERIVATIVE FOR THE TREATMENT OF ALLERGY DISEASES |
CA2407964A1 (en) * | 2000-05-19 | 2001-11-29 | Alcon, Inc. | Disulfide derivatives useful for treating allergic diseases |
JP2002193796A (en) * | 2000-12-27 | 2002-07-10 | Ajinomoto Co Inc | Inhibitor to activation of inflammatory factor, usage thereof and new polysulfide derivative usable for the same |
-
2001
- 2001-04-25 DK DK01930719T patent/DK1289945T3/en active
- 2001-04-25 WO PCT/US2001/013242 patent/WO2001090059A1/en active IP Right Grant
- 2001-04-25 MX MXPA02011480A patent/MXPA02011480A/en active IP Right Grant
- 2001-04-25 AU AU2001257227A patent/AU2001257227B2/en not_active Ceased
- 2001-04-25 KR KR1020027014931A patent/KR20020093982A/en not_active Application Discontinuation
- 2001-04-25 JP JP2001586248A patent/JP2003534317A/en active Pending
- 2001-04-25 EP EP01930719A patent/EP1289945B1/en not_active Expired - Lifetime
- 2001-04-25 AU AU5722701A patent/AU5722701A/en active Pending
- 2001-04-25 CN CNB018094759A patent/CN1173697C/en not_active Expired - Fee Related
- 2001-04-25 TR TR2004/02299T patent/TR200402299T4/en unknown
- 2001-04-25 US US09/841,898 patent/US6372802B2/en not_active Expired - Fee Related
- 2001-04-25 AT AT01930719T patent/ATE272619T1/en not_active IP Right Cessation
- 2001-04-25 PT PT01930719T patent/PT1289945E/en unknown
- 2001-04-25 DE DE2001604690 patent/DE60104690T2/en not_active Expired - Fee Related
- 2001-04-25 PL PL01365459A patent/PL365459A1/en not_active Application Discontinuation
- 2001-04-25 CA CA002408145A patent/CA2408145A1/en not_active Abandoned
- 2001-04-25 BR BR0110845-0A patent/BR0110845A/en not_active IP Right Cessation
- 2001-04-25 ES ES01930719T patent/ES2222370T3/en not_active Expired - Lifetime
- 2001-05-15 AR ARP010102302A patent/AR028565A1/en not_active Application Discontinuation
-
2002
- 2002-01-31 US US10/062,377 patent/US6452052B1/en not_active Expired - Fee Related
- 2002-10-31 ZA ZA200208839A patent/ZA200208839B/en unknown
-
2003
- 2003-04-26 HK HK03102989A patent/HK1050677A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1289945B1 (en) | Aniline disulfide derivatives for treating allergic diseases | |
EP1282599B1 (en) | Disulfide derivatives useful for treating allergic diseases | |
AU2001257227A1 (en) | Aniline Disulfide Derivatives for Treating Allergic Diseases | |
AU2001255675A1 (en) | Disulfide derivatives useful for treating allergic diseases | |
EP1284722B1 (en) | Compositions containing a benzamide disulfide derivative for treating allergic diseases | |
AU2001253807A1 (en) | Compositions containing a benzamide disulfide derivative for treating allergic diseases |